Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 26;13:20406207221080743. doi: 10.1177/20406207221080743

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — MCL treatment algorithm.

BiTE, bispecific T-cell engager; BR, bendamustine and rituximab; BTK, Bruton’s tyrosine kinase; CAR-T, chimeric antigen receptor-T cell; CHOP, cyclophosphamide, vincristine, doxorubicin, and prednisone; Mod, modified; mTOR, mammalian target of rapamycin; RDHAP, rituximab, dexamethasone, cytarabine, and cisplatin; R-HyperCVAD, rituximab in combination with hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone; V, bortezomib; VcR-CVAD, bortezomib with modified R-HyperCVAD; VR-CAP, bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone.